Neoadjuvant chemotherapy for advanced gastric cancer: A meta-analysis

Table 1 Basic characteristics of trials included in this study

Author and year of publication (citation)	Country	Patients (n)		NAC group		Control group		Median follow-up (mo)
		NAC	Control	Pre-op	Post-op	Pre-op	Post-op
Schuhmacher et al[18], 2009	Germany	72	72	5-FU + DDP	None	None	None	53
Boige et al[19], 2007	France	113	111	FP	FP	None	None	68
Cunningham et al[20], 2006	UK	250	253	ECF	ECF	None	None	47
Hartgrink et al[21], 2004	Holland	27	29	FAMTX	None	None	None	83
Nio et al[22], 2004	Japan	102	193	UFT (oral)	CT	None	CT	83
Zhang et al[23], 2004	China	37	54	IV (no details)	None	None	None	NR
Kobayashi et al[24], 2000	Japan	91	80	5-FU (oral)	CT	None	None	NR
Wang et al[25], 2000	China	30	30	5-FU (oral)	None	None	None	NR
Takiguchi et al[26], 2000	Japan	123	139	5-FU ± DDP	None	None	None	NR
Lygidakis et al[27], 1999	Greece	39	19	IP (no details)	CT	None	None	NR
Kang et al[28], 1996	Korea	53	54	PEF	PEF	None	PEF	> 36
Masuyama et al[29], 1994	Japan	24	98	EAP (IA)	None	None	None	> 36
Yonemura et al[30], 1993	Japan	29	26	PMUE	None	None	PMUE	24
Nishioka et al[31], 1982	Japan	64	59	5-FU (oral)	CT	None	CT	> 60

NAC: Neoadjuvant chemotherapy; 5-FU: 5-fluorouracil; DDP: Cisplatin; FP: 5-FU/cisplatin; ECF: Epirubicin/cyclophosphamide/5-FU; FAMTX: 5-FU/adriamycin/methotrexate; UFT: Tegafur/uracil; CT: Chemotherapy; IV: Intravenous; IP: Intraperitoneal; PEF: Cisplatin/epirubicin/5-FU; EAP: Epirubicin/adriamycin/cisplatin; PMUE: Cisplatin/mitomycin C/etoposide/UFT.